OMTN, Volume 28

Supplemental information

RPS4XL encoded by Inc-Rps4I inhibits

hypoxia-induced pyroptosis by binding

HSC70 glycosylation site

Yiying Li, Junting Zhang, Hanliang Sun, Xiufeng Yu, Yujie Chen, Cui Ma, Xiaodong Zheng, Lixin Zhang, Xijuan Zhao, Yuan Jiang, Wei Xin, Shanshan Wang, Jiye Hu, Mingge Wang, and Daling Zhu

Supplemental Figures



Supplemental Figure 1. Establishment of a hypoxia model in Inc-Rps4l-

overexpressing transgenic mice. (A) RV/(LV+S) of Rps4lTg and WT hypoxic and normoxic mice. (B) Echocardiographic images of Rps4lTg and WT hypoxic and normoxic mice. (C) Right ventricular systolic pressure (RVSP) of Rps4lTg and WT hypoxic and normoxic mice. All values are represented as the mean \pm SEM (*p<0.05, **p<0.01, and ***p< 0.001; n \geq 3). WT, wild type; NOR, normoxia; HYP, hypoxia.



Supplemental Figure 2. (A) Overexpression efficiency of lnc-Rps4l. (B–F) Western blotting analysis of (B) c-caspase-1, (C) NLRP3, (D) ASC, (E) IL-1 β , and (F) IL-18 in hypoxic and normoxic PASMCs transfected with OE-Rps4l or OE-NC. All values are represented as the mean ± SEM (*p<0.05, **p<0.01, and ***p< 0.001; n ≥ 3). NOR, normoxia; HYP, hypoxia. All values are represented as the mean ± SEM (*p<0.05, **p<0.01, and ***p< 0.001; n ≥ 3). NOR, normoxia; HYP, hypoxia.



Supplemental Figure 3. Inc-Rps4I-encoded peptide RPS4XL attenuates hypoxiainduced pyroptosis *in vivo*. (A–E) Protein expression analysis of (A) c-caspase-1, (B) NLRP3, (C) ASC, (D) IL-1β, and (E) IL-18 in the lung tissues of hypoxic mice infected with AAV9-NC, AAV9-Rps4l, and AAV9-mut. All values are represented as

the mean \pm SEM (*p<0.05, **p<0.01, and ***p< 0.001; n \ge 3). NOR, normoxia; HYP, hypoxia.



Supplemental figure 4. Exogenous RPS4XL inhibits hypoxia-induced pyroptosis

in human PASMCs. (A–E) Western blotting analysis of (A) c-caspase-1, (B)

NLRP3, (C) ASC, (D) IL-1 β , and (E) IL-18 in human PASMCs treated with 5 μ g/ml,

7.5 µg/ml, or 10 µg/ml RPS4XL under hypoxic conditions. All values are represented

as the mean \pm SEM (*p<0.05, ** p<0.01, and ***p<0.001; n \ge 3). NOR, normoxia;

HYP, hypoxia; NS, no significance.



Supplemental figure 5. HSC70 is up-regulated under hypoxic conditions. (A) Western blotting analysis of HSC70 in hypoxic and normoxic PASMCs. (B) HSC70 protein expression in the lung tissues of Rps4lTg and WT hypoxic and normoxic mice. (C) Western blotting analysis of HSC70 in PASMCs treated with 5 µg/ml, 7.5 µg/ml, or 10 µg/ml RPS4XL under hypoxic conditions. Flag was used as a negative control. All values are represented as the mean \pm SEM (**p*<0.05, ***p*<0.01, and ****p*< 0.001; n \geq 3). WT, wild type; NOR, normoxia; HYP, hypoxia.



Supplemental Figure 6. Interference efficiency of HSC70 RNAi in PASMCs. (A) Interference efficiency of *HSC70* mRNA levels. (B) Interference efficiency of HSC70 at the protein level. All values are represented as the mean \pm SEM (** p<0.01, and ***p < 0.001; n \geq 3).





C c-Caspase-1 β-actin 45kDa 43kDa 43kDa 43kDa 43kDa 43kDa











Supplemental figure 7. Interfering with HSC70 inhibits hypoxia-induced

pyroptosis of PASMCs. (A) LDH release assay in hypoxic and normoxic PASMCs transfected with SI-HSC70, or SI-NC. (B) PI staining in hypoxic and normoxic PASMCs transfected with SI-HSC70, or SI-NC (Scale bar = 50 μ m). (C-G) WB analysis of (C) c-Caspase-1 (D) NLRP3, (E) ASC, (F) IL-1 β and (G) IL-18 in hypoxic and normoxic PASMCs transfected with SI-HSC70, or SI-NC. All values are represented as the mean ± SEM (**p*<0.05, ***p*<0.01, and ****p*< 0.001; n ≥ 3). NOR, normoxia; HYP, hypoxia.



Supplemental Figure 8. Global and local quality estimates and standardized QMEAN4 scores of the RPS4XL domains using a structure model. (A) Global quality (B) Local quality estimate (C) Standardized QMEAN4 scores for the RPS4XL 1–41 aa domain. The (D) global quality, (E) local quality estimate, and (F) standardized QMEAN4 scores for the RPS4XL 42–104 aa domain. The (G) global quality, (H) local quality estimate, and (I) standardized QMEAN4 scores for the

RPS4XL 105–262 aa domain.



Supplemental Figure 9. RPS4XL does not bind to the 394-509 aa or 510-646 aa

HSC70 domains. Microscale thermophoresis of the HSC70 (A) 394–509 aa and (B)

510-646 aa domains when combined different concentrations of RPS4XL.

۸											
~	Name: sp_P6 MSKGPAVG1DLG AVVQSDMKHWPF AGT1AGLNVLR1 F1AEFKRKHKKD LRDAKLDKSQ1H	3017_HSP7 CTTYSCVCVF MVVNDAGRF INEPTAAAI DISENKRAVF IDIVLVGGS1	C_MOUSE Len PGHGKVEIIANDQ PKVQVEYKGETKS AYGLDKKVGAER RRLRTACERAKRT PRIPKIQKLLQDF	gth: GNRT1 FYPEE NVLIF LSSS1 FNGKE . N	393 PSYVAFTD VSSMVLTK DLGGGTFD QASIEIDS LNKSINPD	TERLIGD/ MKEIAEAY /SILTIEI LYEGIDFY EAVAYGAA	AAKNQ YLGKT DGIFE YTSIT AVQAA	VAMNPTNTV VTNAVVTVI VKSTAGDTF RARFEELNA ILSGDKSEN N.	FDAKRL PAYF <mark>NDS</mark> ILGGEDFI ADLFRGTI IVQDLLL	I GRRFDD QRQATKD DNRMVNH LDPVEKA	80 160 240 320 80 160 240 320
_	• • • • • • • • • • • •	• • • • • • • • • •		• • • • •	. N		• • • •	• • • • • • • • •	• • • • • •		400
В											
	(Threshold=0	5)									
	SeqName	Position	Potential	Jury	N-Glyc						
			agr	eemen	t result						
	sp_P63017_HS sp_P63017_HS sp_P63017_HS	SP7C_MOUSE SP7C_MOUSE SP7C_MOUSE	35 NRTT 62 NPTN 151 NDSQ	0.646 0.783 0.556	3 (8/9 0 <mark>(9/9</mark> 4 (8/9)) +))) +	WAR	NING: PRO	X1.		
	sp_P63017_HS	P7C_MOUSE	360 NKSI	0. 578	8 (8/)) +					
С											
	Name: sp_P6 MSKGPAVGIDL0	63017_H GTTYSCVGVI	I FQHGKVEIIANDO	Lengt	h: 393 TPSYVAFTI	TERLIG	AAKN	QVAMNPTNI	VFDAKR	LIGRRFDD	
	AVVQSDMKHWPF	FMVVNDAGRI	PKVQVEYKGETKS	SEVPE	EVSSMULTE	MKETAEA	YL.GK	TVTNAVVTV	PAYEND	SOROATKD	
	AGTIAGUNVLRI	INEPTAAA	TAYGLDKKVGAEI	RNVL.T	FDLGGGTFI	VSILTIE	DGIE	EVKSTAGDT	HLGGED	FDNRMVNH	
	FIAFEKPKHKKI	TSENKRAVI	PRI RTACERAKR	TI 999		VEGIDE	VTST	TRAPEFEIN	IADI FRC	TIDPVEKA	
	I DDAVI DVSOTI	DIVI VCCS	TRENTACENANN	PENCK	LAURG INDI	EAVAVCA	AVOA	ATLCORGE	NUODII	ILDI VERA	
	LENDARLDKSQII	IDIALAGOS.	INTENTØNELØDI	FINGK	PENUS INL	BAVAYGA	in vQA	UIT20DV2F	NYQUEL	6	
	•••••			• • • •	• • • • • • • • • •	• • • • • • • •	• • • • •	• • • • • • • • • •	• • • • • • •		
	•••••	•••••		••••		• • • • • • • •	• • • • •		• • • • • • •		
	• • • • • • • • • • • • •	• • • • • • • • • •	• • • • • • • • • • • • • • • •	• • • •	• • • • • • • • • •	• • • • • • •			• • • • • • •		
	• • • • • • • • • • • • •	• • • • • • • • • •	• • • • • • • • • • • • • • • •	• • • •	• • • • • • • • • •	• • • • • • • •					
-	• • • • • • • • • • • • •	• • • • • • • • • •	• • • • • • • • • • • • • • • •	• • • •	• • • • • • • • • •	• • • • • • •		• • • • • • • • • •	• • • • • • •		
D											
	Name		S/T	Pos	G-score	T-score	Y∕N	Comment			
							-,			-	
	sp P63017 H		S	2	0.422	0.386		-			
	sp_P63017_H		Т	13	0.283	0.027		-			
	sp_P63017_H		Т	14	0.273	0.071		-			
	sp_P63017_H		S	16	0.164	0.026		-			
	sp_P63017_H		Т	37	0.293	0.031		-			
	sp_P63017_H		Т	38	0.283	0.192	•	-			
	sp_P63017_H		S	40	0.216	0.021	•	-			
	sp_P63017_H		Т	45	0.318	0.053	•	-			
	sp_P03017_H		T	47	0.295	0.053	•	-			
	sp_P03017_H		I T	66	0.201	0.140	•	-			
	sp_P03017_H		1 c	95	0.210	0.021	•	_			
	sp_F03017_H		э Т	111	0.105	0.033	•	_			
	sp_r03017_H		2	113	0.000	0.032	•	_			
	sp_103017_H		- -	120	0.220	0.022	•	_			
	sp_P63017_H		Š	121	0.188	0.073		_			
	sp P63017 H		Ť	125	0.314	0.056		_			
	sp_P63017_H		Т	138	0.270	0.020		-			
	sp_P63017_H		Т	140	0.262	0.079		-			
	sp_P63017_H		Т	145	0.292	0.198		-			
	sp_P63017_H		S	153	0.259	0.019		-			
	sp_P63017_H		Т	158	0.283	0.077	•	-			
	sp_P63017_H		T	163	0.265	0.147	•	-			
	sp_P03017_H		T	111	0.230	0.043	•	-			
	sp_P03017_H		1	204	0.190	0.049	•	-			
	sp_P03017_H		3 T	208	0.127	0.021	•	_			
	sp_103017_H		2	221	0.244	0.013	•	_			
	sp_P63017_H		т	222	0.255	0.278		_			
	sp_100017_H		Ť	226	0.237	0.023		_			
	sp_P63017_Н		S	254	0.117	0.054		-			
	sp P63017 H		Т	265	0.281	0.045		_			
	sp_P63017_H		Т	273	0.319	0.031		-			
	sp_P63017_H		S	275	0.219	0.060		-			
	sp_Р63017_Н		S	276	0.214	0.024		-			
	sp_P63017_H		S	277	0.216	0.020		-			
	sp_P63017_H		Т	278	0.294	0.038	•	-			
	sp_P63017_H		S	281	0.223	0.082	•	-			
	sp_P63017_H		S	286	0.196	0.023	•	-			
	sp_F63017_H		Т	295	0.190	0.062	•	-			
	sp_F63017_H		S	296	0.117	0.041	•	-			
	sp_F03U17_H		T	298	0.177	0.049	·	-			
	sp_r03017_H		Т	313	0.180	0.029	•	_			
	sp_r03017_H		2	340	0.174	0.019	·				
				-04U	0.090	0.002	-	-			
	sp_P03017_H		T	3/1	0 150	0.061	•	_			
	sp_P63017_H sp_P63017_H sp_P63017_U		T	341 362	0.150	0.061		-			
	sp_P63017_H sp_P63017_H sp_P63017_H sp_P63017_H		T S S	341 362 381	0.150 0.121 0.155	0.061 0.325 0.070		-			
	sp_P63017_H sp_P63017_H sp_P63017_H sp_P63017_H sp_P63017_H		T S S	341 362 381 385	0.150 0.121 0.155 0.203	0.061 0.325 0.070 0.059	•				

Supplemental Figure 10. Prediction of N-glycosylation and O-glycosylation sites

in the 1–393 aa domain of HSC70. (A and B) Bioinformatics prediction of Nglycosylation site in the 1–393aa domain of HSC70 using NetNGlyc. (C and D) Bioinformatics prediction of O-glycosylation site in 1–393 aa domain of HSC70 using DictyOGlyc.



Supplemental Figure 11. The glycosylation inhibitor tunicamycin inhibits

hypoxia-induced pyroptosis in PASMCs. (A) LDH release in PASMCs treated with 1 μ g/ml tunicamycin under hypoxia. (B) PI staining in PASMCs treated with 1 μ g/ml tunicamycin under hypoxia (Scale bar = 50 μ m). (C-G) Western blotting analysis of (C) HSC70, (D) c-caspase-1, (E) ASC, (F) IL-1 β , and (G) IL-18 in PASMCs treated with 1 μ g/ml tunicamycin under hypoxia. All values are represented as the mean \pm SEM (*p<0.05, **p<0.01, and ***p< 0.001; n \geq 3). NOR, normoxia; HYP, hypoxia; Tu; tunicamycin.